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ABSTRACT
Background/aims Surveillance of people with 
previously successfully treated diabetic macular oedema 
(DMO) and proliferative diabetic retinopathy (PDR) adds 
pressure on ophthalmology services. This study evaluated 
a new surveillance pathway entailing multimodal 
imaging reviewed by trained ophthalmic graders and 
compared it with the current standard care (face- to- face 
evaluation by an ophthalmologist).
Methods Cost analysis of the new ophthalmic grader 
pathway, compared with the standard of care, from the 
perspective of the UK National Health Service, based on 
evidence from the Effectiveness of Multimodal imaging 
for the Evaluation of Retinal oedema And new vesseLs 
in Diabetic retinopathy study. Resource use data were 
prospectively obtained including times to undertake 
each procedure. Effectiveness was assessed in terms of 
sensitivity and specificity of referral decisions in the grader 
pathway. Costs (SDs) were analysed per 100 patients 
separately for DMO and PDR at 2018/2019 costs.
Results For DMO, where sensitivity was very high 
(97%), the cost difference (savings) for the grader’s 
pathway would be £1390 per 100 patients. For PDR, 
the cost would be reduced by £461 for seven- field 
Early Treatment for Diabetic Retinopathy Study (ETDRS) 
images and by £1889 for ultrawide field images, per 
100 patients. Ultrawide images required less time to 
be obtained and read than seven- field ETDRS. The real 
savings would be in ophthalmologist time, which could 
be then redirected to the evaluation of people at high 
risk of visual loss.
Conclusions Surveillance of people with previously 
successfully treated DMO and PDR by trained ophthalmic 
graders can achieve satisfactory results and release 
ophthalmologist time.
Trial registration numbers NCT03490318, 
ISRCTN10856638.
INTRODUCTION
Retinal complications of diabetes, namely diabetic 
macular oedema (DMO) and proliferative diabetic 
retinopathy (PDR), can lead to sight loss. In many 
people, DMO and PDR are treated successfully 
with laser photocoagulation and/or antivascular 
endothelial growth factor (anti- VEGF) therapies. 
However, both can recur following successful treat-
ment, so long- term surveillance is necessary.
The number of people with diabetes is increasing 
and the numbers attending ophthalmology clinics 
continue to rise, despite improvements in glycaemic 
control and screening for DR have reduced the risk 
of advanced retinopathy.1 This makes it difficult for 
ophthalmology clinics to meet the demand and, as 
a result, detrimental delays in the evaluation and 
treatment of patients occur.2
National Institute for Health and Care Excel-
lence (NICE) recommends treatment of severe 
DMO (with central retinal thickness on spectral- 
domain optical coherence tomography (SD- OCT) 
of >400 µm) with anti- VEGFs after which patients 
should usually be followed monthly during the first 
year of treatment, and every 1–3 months thereafter 
to detect recurrence.3 4 In less severe cases, NICE 
advices macular laser, which is applied in a single 
session and patients followed subsequently every 
3–4 months.
PDR is currently treated with laser panretinal 
photocoagulation (PRP); treatment with anti- VEGF 
drugs is being introduced.5 After PRP, patients 
are followed at 6–12 monthly intervals to detect 
recurrence.
Given the chronic nature of DMO and PDR and 
the possibility of recurrence, follow- up is lifelong.
Currently in the National Health Service (NHS), 
ophthalmologists assess patients during follow- up 
using SD- OCT for DMO and fundus examination 
by slit- lamp biomicroscopy for PDR. Retinal photo-
graphs are not routinely taken to evaluate PDR.
Standard cameras cannot image the retinal 
periphery and much of the retina is not photo-
graphed in the standard seven- field Early Treatment 
for Diabetic Retinopathy Study (ETDRS) images. 
Newer ultrawide field (UWF) imaging (Optos, 
Dunfermline, Scotland, UK) captures nearly the 
entire retina in a single image; with three images 
(centre, superior and inferior) the whole retina is 
covered.
The Effectiveness of Multimodal imaging 
for the Evaluation of Retinal oedema And new 
vesseLs in Diabetic retinopathy (EMERALD) 
study assessed the diagnostic accuracy of a 
new surveillance pathway (ophthalmic grader 
pathway) compared with the current standard of 
care (ophthalmologist face- to- face examination) 
for people with previously successfully treated 
DMO and/or PDR. Diagnostic accuracy results of 








ol: first published as 10.1136/bjophthalm




2 Maredza M, et al. Br J Ophthalmol 2021;0:1–6. doi:10.1136/bjophthalmol-2021-318816
Clinical science
EMERALD have been reported.6 Herein, we present cost anal-
yses, comparing the ophthalmic grader and standard of care 
pathways. If the grader pathway is as sensitive at detecting 
reactivation, graders could take over much of the routine 
surveillance. Specificity is also important, since the propor-
tion referred by graders to ophthalmologists determines the 
savings in their time. We also compare costs of UWF fundus 
images with those of seven- field ETDRS.
PATIENTS AND METHODS
Study background
EMERALD was a diagnostic accuracy study7 in adults with 
type 1 or 2 diabetes and previously successfully treated DMO/
PDR who, at the time of enrolment, had reactivated or inactive 
disease, recruited from 13 ophthalmology departments in the UK. 
The primary outcome was sensitivity of the ophthalmic grader 
pathway to detect presence of DMO and active PDR, using stan-
dard care as reference standard, which included slit- lamp exam-
ination and review of SD- OCT scans by an ophthalmologist.
The ophthalmic grader pathway entailed review of SD- OCT 
scans to detect DMO, and seven- field ETDRS and UWF images 
to detect PDR, by trained, tested and certified ophthalmic 
graders. The analysis took into consideration ophthalmic graders 
referring to ophthalmologists all patients diagnosed as having 
DMO and/or active PDR, or if they were uncertain about the 
diagnosis, or if images were ungradable, as this is what would 
occur in clinical practice if the pathway is implemented. As new 
vessels may be seen on fundus images but missed on fundus 
examination, the study included an enhanced reference standard 
for PDR. The latter combined results of face to face examina-
tion by the ophthalmologists with the evaluation of seven- field 
ETDRS and UWF images by an ophthalmologist expert in DR; 
if any detected active PDR, the grading, based on the enhanced 
reference standard, was active PDR.
Cost analysis
Costs of standard care, ophthalmic grader pathway and enhanced 
reference standard included staff costs (based on time under-
taken to perform activities/procedures), equipment costs and 
costs of training graders. The cost analysis was undertaken from 
the perspective of the UK NHS.3 All costs were at a single time 
point, expressed in £ sterling and valued in 2018–2019 prices.
Measurement and valuation of resource use
Resource use was captured prospectively on case report forms 
(CRFs) at each participant’s routine standard care visit. CRFs 
captured the time taken to:
 ► Undertake best- corrected visual acuity.
 ► Obtain SD- OCT, seven- field ETDRS and UWF images by 
ophthalmic photographers/imaging technicians.
 ► Undertake face- to- face examination by the ophthalmologist, 
including slit- lamp biomicroscopy, review of SD- OCT scans 
(to detect DMO) and counselling the patient. However, for 
the base- case analysis, we used the NHS standard reference 
cost for an Ophthalmology outpatient visit to cost the stan-
dard care pathway. That unit cost captures the reading of 
SD- OCT by ophthalmologists.
 ► Grade SD- OCT, seven- field ETDRS and UWF images by 
ophthalmic graders.
 ► Grade seven- field and UWF images by the ophthalmologist 
to set the enhanced reference standard.
Times were converted into staff costs by multiplying the 
number of hours that staff worked by their hourly salary. We 
obtained hourly staff costs from the Personal Social Services 
Research Unit's (PSSRU’s) Unit Costs of Health and Social Care 
compendium8 and NHS reference costs.9 Graders were costed at 
band 7 salary scale while photographers/imaging technicians at 
band 6 level (online supplemental appendix, table A1). All staff 
costs reflect NHS salary, superannuation, national insurance and 
overhead costs.
To calculate an annual equivalent cost of equipment, we annu-
itised capital costs of the item over its useful life span, applying 
a discount rate of 3.5% per annum (online supplemental 
appendix, table A2).10 Equipment cost (including annual main-
tenance costs) was used to derive a per- patient cost of equipment 
assuming that outpatient throughput for the eye department is 
9000 patient visits per year.
Costs of training graders were based on the training delivered 
in EMERALD to ophthalmic graders and included: (1) costs 
of preparing training materials; (2) time costs of two trainers 
delivering a face- to- face meeting over 2 days; (3) salary costs of 
graders for 2 days; (4) costs of travel to attend the face- to- face 
meeting; (5) costs of half- day web- based ‘further’ training for all 
graders, (6) costs of half- day web- based training for graders who 
failed the test at first attempt (who had the opportunity to retake 
it again) and (7) costs of live webinar licence. To follow recom-
mendation that investment costs of education should always 
be included when evaluating the cost- effectiveness of different 
approaches to using health service staff11 we discounted training 
costs at 3.5% p.a., assuming effects of training received will last 
approximately 10 years. Further details on how graders were 
trained are reported elsewhere.6
Sensitivity analyses
We compared costs of delivering the pathways based on the 
main analysis but also based on other scenarios (eg, specifically 
detecting active disease), as prespecified in the EMERALD 
Study Statistical Analysis Plan (online supplemental appendix, 
table A3). In addition, we conducted an exploratory evalua-
tion to assess graders’ performance in referring active PDR 
against an enhanced reference standard consisting of the 
ophthalmologist face- to- face examination supplemented by 
reading of retinal photographs. For costing purposes, costs of 
the enhanced reference standard included reading only one set 
of images, as this is how it would be done if the pathway were 
to be implemented.
Analyses of cost data
We estimated mean costs and SDs of each procedure, including 
obtaining and reading images (UWF, OCT and seven- field 
ETDRS). The costs (SDs) are presented per 100 patients. For the 
standard care pathway costs are simply the reference standard 
costs for an ophthalmology outpatient visit multiplied by 100, 
which include taking and reading SD- OCT images. Costs for the 
grader pathway options take into account the specificity. Thus, if 
the specificity of the grader pathway was 50%, half the patients 
with no active disease would be seen by ophthalmologists. The 
final costs for the grader pathway would therefore include the 
costs of photographer taking images+grader reading images for 
100 patients+ophthalmologists’ time of reviewing patients clas-
sified as possibly active DMO/PDR when DMO/PDR is actually 
inactive, based on specificity.
Missing data
EMERALD was a cross- sectional study with no follow- up. Images 
were taken on the same day patients saw the ophthalmologist 
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and CRFs were completed then. Thus, lost to follow- up was not 
an issue. In a few individuals recorded values seemed unrealistic, 
for example, where times to perform a task were close to 0 or 
more than 60 min and when images were missing. We excluded 
these from the analysis.
Longer-term economic modelling
The study protocol allowed for decision- analytical modelling 
to estimate the longer- term cost- effectiveness of the ophthalmic 
grader pathway. Use of a lifelong time horizon may be warranted 
if observed differences in sensitivity between the new pathway 
tested and the current standard care were sufficient to affect 
visual outcomes for either PDR or DMO. We concluded that 
long- term modelling was not necessary, as sensitivity of the new 
pathway was similar to that of current standard care for DMO. 
For PDR, the overall sensitivity was lower but considered accept-
able, especially for high- risk PDR. In addition, there are data 
gaps for several key items, including rate of progression and 
visual consequences of re- activated PDR in people previously 
treated with PRP, and the proportion that would be picked up at 
the next routine visit.
RESULTS
Table 1 shows the average and median time taken in minutes to 
complete specified procedures by ophthalmologists, graders and 
imaging technicians.
Table 2 presents costs of procedures. Costs for obtaining 
and reading images were lower with UWF compared with 
seven- field ETDRS. We estimated an annual discounted cost of 
training graders of £198.70 per grader, but this cost is trivial 
once divided by the number of patient images that graders would 
read in a year.
Costs of surveillance of people with DMO and PDR
DMO: comparison of ophthalmic grader pathway with current 
standard care
Table 3 shows costs of follow- up of DMO by ophthalmic graders 
and ophthalmologists. The cost analysis takes into account refer-
rals by the grader, which would include those related to ‘active 
DMO’ (ie, grader believes there is recurrence of DMO), ‘unsure’ 
(ie, grader thinks there may be recurrence of DMO but is not 
fully sure) and ‘ungradable’ (ie, reader is unable to grade the 
image). The estimated mean cost of surveillance of people with 
DMO per 100 patients was £4410.00 for ophthalmic graders 
compared with £5800.00 for standard care. The mean differ-
ence (cost savings) per 100 patients would be £1390.00. The 
real savings would be in ophthalmologist time, released for other 
purposes. It should be noted that savings would only apply if 
neither eye had DMO nor active PDR as otherwise the patient 
would still require an ophthalmologist evaluation.
All sensitivity analyses (SENA) (online supplemental appendix, 
tables A4–A7) supported the main finding that surveillance by 
Table 1 Time (in minutes) taken to complete specified activities per patient by ophthalmic photographers/imaging technicians, ophthalmic 
graders and ophthalmologists
Time- related activity N Mean SD Median Q1 Q3 IQR
Standard care** 380 15.3 7.6 14.0 10.0 19.0 9.0
Ophthalmic photographer/imaging technician obtaining seven- field ETDRS images 267 15.1 8.4 13.0 10.0 18.0 8.0
Ophthalmic photographer/imaging technician obtaining UWF images 272 10.3 6.6 9.0 5.0 14.0 9.0
Ophthalmic grader reading seven- field ETDRS images 267 10.6 6.5 9.0 7.0 13.0 6.0
Ophthalmic grader reading UWF images 264 9.3 5.9 8.0 5.0 11.5 6.5
Ophthalmologist reading seven- field ETDRS images 268 11.9 5.00 11.0 9.0 15.0 6
Ophthalmologists reading UWF images 268 10.1 4.0 9.5 7.0 12.0 5.0
Ophthalmic grader reading SD- OCT images 248 4.2 3.3 4.0 3.0 5.0 2.0
The standard of care pathway includes all patients (n=380 of the full total of 397 in EMERALD; 17 are not included as the times provided for some of the procedures were 
considered not plausible, being either too high or too low). Note there were 272 patients eligible for grader pathway with DMO and 281 eligible with PDR.
*Ophthalmologists face- to- face evaluation of patients with access to SD- OCT images.
EMERALD, Effectiveness of Multimodal imaging for the Evaluation of Retinal oedema And new vesseLs in Diabetic retinopathy; ETDRS, Early treatment diabetic retinopathy study; 
Q1, Quartile 1; Q3, Quartile 3; SD- OCT, spectral domain optical coherence tomography; UWF, ultra wide field.
Table 2 Costs of procedures
Item Cost per patient (SD) Notes
Standard care* (base case) £58.00 NHS 2019/2020 national tariff for an ophthalmology 
outpatient follow- up appointment with a consultant
Ophthalmic photographer/imaging technician obtaining seven- field ETDRS images (band 6) £12.78 (6.83) Time cost × photographer salary+equipment cost
Ophthalmic photographer/imaging technician obtaining UWF images (Band 6) £9.75 (5.85) Time cost × photographer salary+equipment cost
Reading ETDRS images by ophthalmic grader (Band 7) £10.45 (6.40) Time cost × grader salary
Reading UWF images by ophthalmic grader (Band 7) £9.10 (5.77) Time cost × grader salary
Reading ETDRS images by ophthalmologist £21.58 (9.02) Time cost × salary
Reading UWF images by ophthalmologist £18.23 (7.28) Time cost × salary
Taking SD- OCT Occurs in both pathways Cost not included
Reading SD- OCT—grader (band 7) £4.08 (3.25) Time cost × salary
Equipment cost is a small % of total cost (see online supplemental appendix table A2). Salary costs include employers’ costs at 20%. Reading SD- OCT by ophthalmologist is 
included in the NHS reference cost for the standard care pathway.
*Ophthalmologists face to face evaluation of patients with access to SD- OCT images.
ETDRS, Early Treatment Diabetic Retinopathy Study; NHS, National Health Service; SD- OCT, spectral domain optical coherence tomography; UWF, ultrawide field.
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graders could provide useful savings in ophthalmologist time. 
Cost savings per 100 patients could range between £810.00 (if 
graders were asked to identify any active DMO in either eye 
possibly requiring treatment) to £2840.00 (if graders were asked 
to identify only central involving active DMO), because of differ-
ences in specificity affecting the proportion of people referred 
to ophthalmologists. Specificity is the main factor driving cost 
differences.
PDR: comparison of ophthalmic grader pathway with current 
standard care
Table 4 shows costs of surveillance of PDR comparing ophthalmic 
grader’s pathway with the standard care. Cost savings from 
graders reading the seven- field ETDRS and UWF images could 
be £461.00 and £1889.00 per 100 follow- up visits respectively, 
because the UWF images take less time to read. The time to 
obtain and read images (table 1) is the main driver of the differ-
ences of costs since the equipment costs were small.
Most (SENA 1 and SENA 2: online supplemental appendix, 
tables A8–9) corroborate the main finding that the ophthalmic 
grader pathway could save ophthalmologist time. Savings would 
be modest or even zero in SENA 4 (online supplemental table 
A10) for ophthalmic graders evaluating seven- field ETDRS 
images for people with pre- retinal or vitreous haemorrhages (ie, 
high- risk PDR); in this group there would be savings with UWF 
imaging.
PDR; comparison with enhanced reference standard
In EMERALD, both ETRDS and UWF images were examined 
in the enhanced standard. If the standard of care for PDR were 
to be supplemented with images in clinical practice, only one set 
of images would be used. Based on the results, we have assumed 
these would be UWF images.
Online supplemental appendix, table A11 shows an analysis 
comparing the ophthalmic graders referral for either eye by 
UWF imaging against standard care combined with either UWF 
imaging or seven- field ETDRS as graded by the ophthalmolo-
gists of active PDR in either eye. Costs using UWF imaging are 
lower than those using seven- field ETDRS images. So, when 
comparing enhanced standard care with the grader pathway, 
costs of UWF images are used. The grader pathway is about half 
the cost of the enhanced reference standard (table 5).
DISCUSSION
Follow- up of DMO after treatment by trained and tested 
ophthalmic graders using SD- OCT was found to have very good 
sensitivity (97%), but lower specificity, ranging from 31% to 
56% depending on the scenario investigated. Even that level of 
specificity would allow useful savings in ophthalmologist time, 
which could be directed for example, to the care of other people 
with visual threatening disease. In PDR, the overall sensitivity of 
the ophthalmic grader pathway was lower than that of DMO, 
but the sensitivity was higher in high risk PDR (pre- retinal and/
or vitreous haemorrhage), nearly reaching 90% if UWF imaging 
was used.
In EMERALD, images were evaluated without any informa-
tion about the patient, with ophthalmic graders (and ophthal-
mologists undertaking the enhanced reference standard) masked 
to clinical data and previous images. Specificity is an important 
factor in the costs of the grader pathway. In routine care it is 
likely that having access to clinical information and previous 
images would improve sensitivity and specificity of the grader 
pathway. For example, it is possible that in the medical records 
the clinician would have recorded there was a macular cyst on 
SD- OCT at the time treatment was stopped; in that case it is 
likely the grader would not refer the patient. Previous images 
would enable for graders to check whether any lesion seen, 
for example, new vessels elsewhere, had been there previously, 
and if so, whether they were unchanged or improved/resolved, 
or whether they were a new finding, reducing inappropriate 
referrals and improving specificity. Access to medical records 
and previous images is now facilitated by the use of electronic 
medical records across the UK (eg, Medisoft, MediSIGHT, 
OpenEyes) and already existing and new platforms (eg, Ophthal-
suite) to view fundus images and SD- OCTs.
One option would be that if the grader sees a questionable 
feature, annotates it (to save ophthalmologist time) and submits 
the image(s) (not the patient) for review by the ophthalmologist. 
This would avoid a proportion of potential referrals.
Table 3 Relative costs of surveillance of people with previously 
successfully treated DMO
Sensitivity Specificity Cost per 100 patients





Grader pathway (band 7) 97% 31% (4.08×100) +(69‡ x 58) = 
£4410.00§
Cost difference £1390.00¶
*Standard care pathway=ophthalmologists face- to- face evaluation of patients with 
access to SD- OCT images.
†Costs for 100 patients in the standard of care pathway.
‡Ophthalmologists' time of reviewing 69% of patients classified as possibly active 
DMO when DMO is inactive, based on specificity.
§Ophthalmic grader costs for reading 100 OCTs+Ophthalmologist costs for 69 x 
standard care visits.
¶Current standard- of- care costs minus ophthalmic grader costs.
DMO, diabetic macular oedema; SD- OCT, spectral- domain optical coherence 
tomography.
Table 4 Cost comparison—ophthalmic grader pathway and standard care pathway
Sensitivity Specificity Cost per 100 patients Cost saving compared with standard care*
Standard care pathway †† Assumed 100% Assumed 100% £5800.00 –
Ophthalmic grader evaluating seven- field ETDRS images* 85% 48% £5339.00 £461.00‡
Ophthalmic grader evaluating UWF images* 83% 54% £4611.00 £1189.00§
*The analysis from which the sensitivity and specificity values are derived in this table are based on either eye being active and referrals to ophthalmologist. *=Grader referral 
for PDR = ‘active’ + ‘unsure’ + ‘ungradable’. The cost will not be increased if both eyes show active PDR.
†Standard care pathway=ophthalmologist face- to- face examination for active PDR in either eye.
‡Calculated as (time of taking ETDRS photos+costs of ophthalmic grader reading ETDRS photos) x100 +(52 × standard of care costs). Because of the specificity, 52% of patients 
will be referred to the ophthalmologist.
§Calculated as (time of taking UWF fundus images+costs of ophthalmic grader reading UWF images)*100 +(46 * standard of care costs). Because of the specificity, 46% of 
patients will be referred to the ophthalmologist.
ETDRS, Early Treatment for Diabetic Retinopathy Study; PDR, proliferative diabetic retinopath; UWF, ultrawide field.
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A more efficient option, although more difficult to organise, 
would be a ‘one- stop’ system in which patients are imaged, 
images graded on the same day (an ophthalmologist could be 
available for advice in situ or remotely), and patient informed of 
the results immediately. As found in the qualitative work under-
taken in EMERALD (see accompanying manuscript by Prior and 
Lois), this would be preferred by patients.
Given the very high number of people referred to ophthal-
mology clinics with DMO and PDR, clinics are finding it diffi-
cult to cope with the demand, resulting in delays in evaluation 
and treatment of patients.12 Delayed treatment leads not only 
to sight loss,2 but can reduce the cost- effectiveness of therapies. 
For example, a reduction in the number of anti- VEGF injections 
during the first year of treatment if patients are not seen and 
treated promptly, would lead to a lesser visual acuity improve-
ment.13 Furthermore, as a result of these increased waiting times, 
the NHS often subcontracts work to private clinics or employs 
locum staff to cope with the demand; an expensive exercise. 
EMERALD showed the new pathway could save ophthalmol-
ogist time; releasing ophthalmologists to see or treat other 
patients could reduce the need for frequent NHS waiting list 
initiatives, saving money to the NHS. Whether or not, however, 
the ophthalmologist’s time released is used efficiently in the 
NHS for other purposes and whether savings are realised will 
depend on an efficient reorganisation of services.
We used national reference costs for England of an ophthal-
mology outpatient appointment. These have sometimes been 
criticised for underestimating true costs, including at NICE 
Technology Appraisal Committee meetings, as noted in the 
NICE guidance on ranibizumab for DMO (TA 274). The true 
cost of an outpatient visit, however, is not known.
Times required to obtain and evaluate UWF images were 
shorter than those of seven- field ETDRS images with compa-
rable sensitivity (higher for high risk PDR). This implies that if 
imaging is added, UWF should be used. In EMERALD, UWF 
images included three fields; if one were to provide comparable 
sensitivity and specificity, this would reduce time to obtain and 
grade images. In EMERALD images were obtained following 
pupillary dilation. If a single UWF image obtained without 
mydriasis provided comparable sensitivity and specificity, 
patient satisfaction would probably increase. Patients would be 
able to drive following the examination, and time in clinic would 
be reduced, as they would not need to wait for their pupils to 
dilate prior to imaging. It would also lead to some savings from 
dilating drops not being required.
We provided training costs for graders as observed in 
EMERALD. If ophthalmic grading is introduced in practice, 
other arrangements might be made, including distant online 
training. Once a comprehensive training set of images of previ-
ously treated patients had been developed, graders could learn 
online at their own pace. This would remove travel costs to face 
to face meetings, which are less appropriate in the COVID-19 
era. There would be initial costs of creating sets of training 
images and supporting material, but there would be no costs of 
ophthalmologist or other trainers doing face- to- face teaching. 
There would be a need for a regular quality assurance system 
after initial training.
EMERALD did not assess the marginal benefits of adding the 
reading of UWF images by ophthalmologists to standard care. 
The marginal cost of this would be ~£28 per patient.
If sensitivity for detecting reactivated PDR was lower than 
ideal and some people with active PDR were missed, the conse-
quences would depend on the rate of progression of the disease. 
This would be expected to be slower in patients previously 
treated by PRP, as those included in EMERALD, than in those 
with treatment- naïve PDR. Furthermore, reactivation might be 
identified at the next follow- up visit before any harm resulted. 
Moreover, patients themselves would be likely to seek care if 
they were to experience floaters or sight loss, for example, due 
to a vitreous haemorrhage. It is possible that in the future some 
people with PDR will be treated with anti- VEGFs, and the rate 
of progression of reactivated PDR after anti- VEGF treatment 
is unknown. It might be faster than after PRP and the conse-
quences more severe.14 15
In conclusion, EMERALD showed that surveillance of 
people with previously successfully treated DMO and PDR by 
ophthalmic graders using multimodal imaging can reduce costs 
and release ophthalmologist time.
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Table 5 Cost and consequence comparison of enhanced reference standard* and grader pathway
Sensitivity Specificity Cost per 100 patients Cost savings
Standard of care+UWF images* Assumed 100% Assumed 100% £8598 –
Ophthalmic Grader evaluating UWF images† 79.7% 58.8% £4263 £4335
*Ophthalmologists face- to- face evaluation of patients with access to SD- OCT images supplemented by the reading by the ophthalmologists of the UWF images.
†In the main analysis, ophthalmic graders refer to ophthalmologists all patients identified as having ‘active PDR’, but also if they were ‘uncertain’ about the diagnosis of if 
‘ungradable’ images.
UWF, ultrawide field.
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